期刊文献+

肝动脉介入灌注化疗/栓塞术前中性粒细胞与淋巴细胞比值对原发性肝癌患者预后的影响 被引量:6

Impact of preoperative peripheral blood neutrophil-to-lymphocyte ratio on prognosis of liver cancer patients undergoing transcatheter arterial chemoembolization
下载PDF
导出
摘要 目的:探讨原发性肝癌(PHC)患者术前中性粒细胞/淋巴细胞比值(NLR)对预后的影响。方法:回顾性分析96例行经导管肝动脉栓塞化疗(TACE)术的PHC患者临床病理资料。根据术前NLR值,分为低NLR组(NLR<2.5)和高NLR组(NLR≥2.5),分析两组患者总生存时间与无进展生存时间;并对其影响预后的危险因素行单因素与多因素分析。结果:全组介入术后,中位总生存时间21.1个月;其中术前高NLR组中位总生存时间16.0个月;术前低NLR组中位总生存时间23.3个月;两组中位生存时间差异有统计学意义(P=0.002)。全组患者中位无进展生存时间13.8个月,其中高NLR组中位无进展生存时间9.6个月,低NLR组中位无进展生存时间17.6个月,两组中位无进展生存时间差异有统计学意义(P=0.011)。单因素分析显示:肝功能Child分级、BCLC分期、AFP、假包膜形成、血供、TACE次数、NLR≥2.5是影响PHC患者TACE术后总生存时间的危险因素(P<0.05)。肝功能Child分级、BCLC分期、假包膜形成、血供、NLR≥2.5是影响PHC患者TACE术后无进展生存时间的危险因素(P<0.05);多因素分析显示,肝功能Child分级、BCLC分期、NLR≥2.5是影响PHC患者TACE术后生存的独立预后因素(P<0.05)。BCLC分期、NLR≥2.5是影响PHC患者TACE术后无进展生存时间的独立预后因素(P<0.05)。结论:术前外周血NLR可作为PHC患者行TACE的预后指标,NLR高者预后差。 Objective:To investigate the impact of the preoperative peripheral blood neutrophil - to - lymphocyte ratio(NLR)on postoperative prognosis of patients with primary hepatic cancer(PHC). Methods:Clinicopathologic data of 96 PHC patients undergoing transcatheter arterial chemoembolization(TACE)were analyzed retrospectively. Based on the preoperative neutrophil - to - lymphocyte ratio(NLR),the patients were divided into low NLR group (NLR 〈 2. 5)and high NLR(NLR≥2. 5)group. The overall survival time and progress - free survival time of the two groups were analyzed,and risk factors that would influence the prognosis of these patients were determined by uni-variate and multivariate analyses. Results:The median overall survival time for the entire group was 21. 1 months, which for high NLR group and low NLR group was 16. 0 and 23. 3 respectively. The difference in the overall survival between the two groups had statistical significance(P = 0. 002). The median progress free survival time for the entire group was 13. 8 months,which for high NLR group and low NLR group was 9. 6 and 17. 6,and there was statistically significant difference in the progression - free survival time between the two groups(P = 0. 011). Univariate analysis showed that liver function Child classification,BCLC staging,AFP,formation of psuedocapsule,blood supply,frequen-cy of TACE and NLR≥2. 5 were the risk factors for the postoperative overall survival time of PHC patients undergoing TACE(P 〈 0. 05),and liver function Child classification,BCLC staging,formation of psuedocapsule,blood supply and NLR≥2. 5 were the risk factors for the postoperative progress - free time of PHC patients undergoing TACE(P 〈0. 05). Multivariate analysis revealed that liver function Child classification,BCLC staging and NLR≥2. 5 were the independent prognostic factors for the survival of PHC patients undergoing TACE(all P 〈 0. 05),and BCLC staging and NLR≥2. 5 were the independent prognostic factors for postoperative progress - free time of PHC patients under-going TACE(P 〈 0. 05). Conclusion:Preoperative peripheral blood NLR can be used as a prognostic predictor of PHC patients undergoing TACE,and those with high NLR face a poor prognosis.
出处 《现代肿瘤医学》 CAS 2015年第19期2798-2801,共4页 Journal of Modern Oncology
关键词 原发性肝癌 中性粒细胞/淋巴细胞比值 肝动脉栓塞化疗术 预后 primary hepatic cancer neutrophil - to - lymphocyte ratio transcatheter arterial chemoembolization prognosis
  • 相关文献

参考文献13

  • 1Jemal A, Bray F, Center MM,et al. Global cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 2Plequezuelo M, Marelli L, Misseri M, et al. TACE versus TAE as therapy for hepatocellular carcionma[ J]. Expert Rev Anticancer T- her,2008,8 (10) :1623 - 1641.
  • 3Kemal Y,Yucel I,Ekiz K,et al. Elevated serum neutrophil to lym- phocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis [ J ]. Asian Pac J Cancer Prev, 2014,15 ( 6 ) : 2651 - 2654.
  • 4商春雨,苏洪英,刘静,韩向军,徐克.原发性肝癌肝动脉化疗栓塞术(TACE)预后多因素分析[J].现代肿瘤医学,2011,19(12):2466-2469. 被引量:49
  • 5刘金明,张克勤,李涛.肝癌多次TACE术后的肝硬化分级及预后因素分析[J].实用癌症杂志,2014,29(1):68-71. 被引量:24
  • 6Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil - to - lymphocyte ratio (NLR) is associated with reduced disease -free survival following curative resection of pancreatic adenocarcinoma [J]. World J Surg,2011,35(4) :868 -872.
  • 7Motomura T, Shirabe K, Mano Y, et al. Neutrophil - lymphocyte ra- tio reflects hepatocellular carcinoma recurrence after liver trans- plantation via inflammatory microenvironment [ J ]. J Hepato1,2013, 58(1) :58 -64.
  • 8Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil - to -lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis [ J ]. Ann Surg, 2013,258 (2) :301 - 305.
  • 9Gong Y, Koh DR. Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model [ J ]. Cell Tissue Res ,2010,339 ( 2 ) :437 - 448.
  • 10Keizman D, Ish - Shalom M, Huang P, et al. The association of pre - treatment neutrophil to lymphocyte ratio with response rate, pro- gression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma [ J]. Eur J Cancer, 2012,48(2) :202 -208.

二级参考文献43

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1469
  • 2张家文,刘斌,张国兵,杜临安,潘发明.166例中晚期肝癌介入治疗预后多因素Cox模型分析[J].安徽医科大学学报,2004,39(5):373-376. 被引量:5
  • 3徐克,于世平.原发性肝癌的肝动脉化疗栓塞治疗[J].中国实用外科杂志,2004,24(8):463-465. 被引量:32
  • 4高思佳,王长龙,何芳显,韩铭钧,姜洪刚,关超,姜宗源.肝癌栓塞后碘油沉积形态与疗效关系的研究[J].中国医科大学学报,1996,25(2):177-180. 被引量:9
  • 5Okuda K,ohtsuki T,Obata H,et al.Natural history of hepatocellular carcinoma and prognosis in relation to treatment[J].Cancer,1985,56:918-928.
  • 6Farinati F,Maria ND,Marafin C,et al.Unresectable hepatocellular carcinoma in cirrhosis:survival,prognostic fator,and unexpected side effects after transcatheter arterial chemoembolization[J].Digest Dis Sci,1996,41:2332-2339.
  • 7Akashi Y.Prognosis of unresectable hepatocellular carcinoma:an evaluation based on multivariate analysis of 90 cases[J].Hepatology,1991,14:262-268.
  • 8Nishimine K,Uchida H,Matsuo N,et al.Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:follow-up CT and therapeutic results[J].Cancer Chemother Pharmacol,1994,33(Supp1):60-80.
  • 9Ando E,Yamashita F,tanaka M,et al.A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein[J].Cancer,1997,79(10):1890-1896.
  • 10Okusaka T,Okada S,Ueno H,et a1.Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma[J].Oncology,2000,58(4):293-299.

共引文献92

同被引文献56

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部